[Serum complement reduction in chronic progressive polyarthritis. II. Behavior of serum complement in the disease course].
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000974:Antibodies, Antinuclear / Q000032:analysis; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000188:drug therapy; D001379:Azathioprine / Q000627:therapeutic use; D001799:Blood Sedimentation; D003165:Complement System Proteins / Q000032:analysis*; D003300:Copper / Q000097:blood; D005260:Female; D006386:Hemagglutination Tests; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D007841:Latex Fixation Tests; D007958:Leukocyte Count; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009504:Neutrophils
D000305:Adrenal Cortex Hormones; D000974:Antibodies, Antinuclear; D003300:Copper; D003165:Complement System Proteins; D001379:Azathioprine; D006854:Hydrocortisone; D008727:Methotrexate
Serum-Komplement-Erniedrigung bei progredient chronischer Polyarthritis (Pep). II. Verhalten des Serumkomplements im Krankheitsverlauf.